Goldman Sachs Names 2 Undervalued Healthcare Stocks to Buy With At Least 50% Upside
Healthcare has long appealed to investors for its growth potential. Within the sector, biotech sits at the riskier end of the spectrum, but it can ...
Tarsus Pharmaceuticals Inc. (TARS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,666,768 | $230,786,378 | +2% | 3.36% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 2,775,649 | $174,699,348 | +9% | 3.27% |
| 3. | Tang Capital Management Kevin C. Tang | 1,568,266 | $98,706,662 | +32% | 4.48% |
| 4. | Millennium Management Israel Englander | 1,427,124 | $89,823,185 | +153% | 0.03% |
| 5. | Vestal Point Capital Ryan Wilder | 1,050,000 | $66,087,000 | +425% | 1.54% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.96 | 1,000 | $18,960.00 | 3,000 | 2023-12-15 | Filing | |
| $16.80 | 9,506 | $159,700.80 | 15,866 | 2023-08-15 | Filing | |
| $16.29 | 6,360 | $103,604.40 | 6,360 | 2022-09-14 | Filing | |
| $16.03 | 12,040 | $193,001.20 | 12,040 | 2022-09-14 | Filing | |
| $13.50 | 100,000 | $1,350,000.00 | 100,000 | 2022-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $80.01 | 66 | $5,280.66 | 94,487 | 2026-09-15 | Filing | |
| $79.00 | 759 | $59,961.00 | 94,553 | 2026-09-15 | Filing | |
| $78.33 | 11,675 | $914,502.75 | 95,312 | 2026-09-15 | Filing | |
| $91.27 | 2,900 | $264,683.00 | 827,991 | 2026-09-04 | Filing | |
| $90.27 | 7,100 | $640,917.00 | 830,891 | 2026-09-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 615,974 | $48,421,716 | 0.05% | |
| 2. | 468,041 | $36,792,703 | 0.27% | |
| 3. | 51,700 | $4,064,137 | 0.01% | |
| 4. | 35,628 | $2,800,717 | 0.06% | |
| 5. | 23,625 | $1,857,161 | 0.03% |
News See All
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2026 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2026 Earnings Call Transcript May 6, 2026Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.40033.
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is among the 10 Fastest Growing NASDAQ Stocks to Buy.
10 Fastest Growing NASDAQ Stocks to Buy
In this article, we will look at the 10 Fastest Growing NASDAQ Stocks to Buy.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2025 Earnings Call Transcript November 4, 2025Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.35.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good afternoon, ladies and gentlemen, and thank you for standing by.
11 Best Breakout Stocks to Buy According to Analysts
In this article, we discuss 11 Best Breakout Stocks to Buy According to Analysts.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Call Transcript February 25, 2025Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.6, expectations were $-0.68.
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
In this article, we discuss the top 10 long-term stock picks of billionaire Joseph Edelman.
Hedge Fund Resource Center